NKG2D/CD314 Protein, Human (HEK293, His-Avi)

Cat. No.:	HY-P78500
Synonyms:	CD314; D12S2489E; KLR; NKG2-D; NKG2D
Species:	Human
Source:	HEK293
Accession:	P26718 (F78-V216)
Gene ID:	100528032
Molecular Weight:	36-38 kDa

PROPERTIES

Biological Activity	1. Immobilized Human NKG2D, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-NKG2D Antibody, hFc Tag with the EC_{50} of 6.6ng/ml determined by ELISA. 2. Immobilized Human NKG2D, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human MICA, hFc Tag with the EC_{50} of 33.4ng/ml determined by ELISA. 3. Immobilized Human NKG2D, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human ULBP-6, hFc Tag with the EC_{50} of 12.9ng/ml determined by ELISA.
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH_2O.
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	NKG2D/CD314 protein operates as an activating and costimulatory receptor essential for immunosurveillance, binding to diverse cellular stress-inducible ligands presented on autologous tumor cells and virus-infected cells. It plays a dual role in innate immune responses, stimulating both activating killer (NK) cells and acting as a costimulatory receptor for T-cell receptors (TCR) in CD8(+) T-cell-mediated adaptive immune responses, enhancing T-cell activation. The receptor facilitates perforin-mediated elimination of ligand-expressing tumor cells, and its signaling cascades involve calcium influx, ultimately leading to TNF-alpha expression. Additionally, NKG2D/CD314 participates in NK cell-mediated bone marrow graft rejection and may regulate the differentiation and survival of NK cells. Its ligand-binding capacity extends to various subfamilies of MHC class I-related glycoproteins, including MICA, MICB, RAET1E, RAET1G, RAET1L/ULBP6, ULBP1, ULBP2, ULBP3

	(ULBP2>ULBP1>ULBP3), and ULBP4. The protein forms homodimers through disulfide linkage and heterohexamers with HCST/DAP10 subunits, a crucial interaction for NK cell surface expression and cytotoxicity induction. Furthermore, it can establish disulfide-bonded heterodimers with CD94 and interacts with CEACAM1, recruiting PTPN6 for VAV1 dephosphorylation, while not interacting with TYROBP.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA